Related Experiment Video
Updated: Jul 13, 2026
An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
The epidemiology and treatment of infections in cancer patients
1Klinikum Ernst von Bergmann, Department of Hematology and Oncology, Charlottenstrasse 72, D-14467 Potsdam, Germany. gmaschmeyer@klinikumevb.de
Abstract:
Significant changes in the epidemiology of infectious complications in cancer patients have emerged during the past decade. Among blood culture isolates from febrile neutropenic patients, Gram-positive pathogens have become predominant, and an increasing spread of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci must be taken into consideration. Risk factors such as indwelling venous catheters or chemotherapy-induced mucosal damage are associated with an increased incidence of Gram-positive infections. Invasive fungal infections, particularly invasive aspergillosis, have become most important in severely neutropenic patients and are associated with fatality rates of 40-60%. The use of nucleoside analogues and the CD52-antibody alemtuzumab induce a long-lasting lymphopenia facilitating the occurrence of opportunistic infections specifically caused by viruses and fungi. In elderly patients undergoing intensive myelosuppressive chemotherapy, infectious complications may be managed as successfully as in younger patients by appropriate antimicrobial therapy. The broad use of fluoroquinolones for antibacterial prophylaxis in neutropenic patients may lead to very high resistance rates among Gram-negative bacilli such as E. coli. In patients given moxifloxacin for infection prevention, unacceptably large numbers of Clostridium difficile-associated enterocolitis have been reported.
Insights
Infectious complications in cancer patients are shifting, with Gram-positive pathogens and invasive fungal infections rising. Careful antimicrobial therapy is key for managing infections in neutropenic patients.
Area of Science:
- Oncology
- Infectious Diseases
- Epidemiology
Background:
- Infectious complications significantly impact cancer patient outcomes.
- Recent epidemiological shifts necessitate updated management strategies for infections in cancer patients.
Purpose of the Study:
- To review the changing epidemiology of infectious complications in cancer patients over the past decade.
- To highlight emerging pathogens and risk factors associated with these infections.
- To discuss the implications for clinical management and antimicrobial stewardship.
Main Methods:
- Review of blood culture isolates from febrile neutropenic patients.
- Analysis of risk factors for Gram-positive and fungal infections.
- Evaluation of antimicrobial resistance patterns and treatment outcomes.
Main Results:
- Gram-positive pathogens are now predominant in febrile neutropenic patients, with increasing prevalence of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
- Invasive fungal infections, particularly invasive aspergillosis, are critical in severely neutropenic patients, carrying high fatality rates (40-60%).
- Specific therapies (nucleoside analogues, alemtuzumab) can lead to lymphopenia, increasing susceptibility to viral and fungal opportunistic infections.
- Widespread fluoroquinolone use has resulted in high resistance rates among Gram-negative bacilli.
- Moxifloxacin prophylaxis has been linked to increased Clostridium difficile-associated enterocolitis.
Conclusions:
- The epidemiology of infections in cancer patients has significantly evolved, requiring vigilance for emerging pathogens and resistance.
- Effective management relies on prompt diagnosis, appropriate antimicrobial therapy, and consideration of host-specific risk factors.
- Antimicrobial stewardship is crucial to mitigate the rise of resistant organisms and C. difficile infections.
Related Concept Videos
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
01:27Tumor Immunotherapy
01:21Cancer Survival Analysis